top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Ron Mayron Biography and Net Worth

Director of Entera Bio

Mr. Mayron is global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa and CEO of S.L.E. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston. Mr. Mayron served as an Officer in the Israeli army achieving the rank of Major.

How do I contact Ron Mayron?: The corporate mailing address for Mr. Mayron and other Entera Bio executives is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. Entera Bio can also be reached via phone at (722) 532-7151 and via email at [email protected]. Learn More on Ron Mayron's contact information.
Has Ron Mayron been buying or selling shares of Entera Bio?: Ron Mayron has not been actively trading shares of Entera Bio during the last quarter. Most recently, on Tuesday, January 18th, Ron Mayron bought 7,000 shares of Entera Bio stock. The stock was acquired at an average cost of $2.80 per share, with a total value of $19,600.00. Learn More on Ron Mayron's trading history.
Who are Entera Bio's active insiders?: Entera Bio's insider roster includes Yonatan Malca (Director), Ron Mayron (Director), and Ramesh Ratan (CFO). Learn More on Entera Bio's active insiders.
Are insiders buying or selling shares of Entera Bio?: In the last year, Entera Bio insiders bought shares 4 times. They purchased a total of 81,067 shares worth more than $56,274.47. The most recent insider tranaction occured on January, 12th when Director Haya Taitel bought 9,500 shares worth more than $9,405.00. Insiders at Entera Bio own 8.9% of the company. Learn More about insider trades at Entera Bio.
Information on this page was last updated on 1/12/2024.

Ron Mayron Insider Trading History at Entera Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/18/2022	Buy	7,000	$2.80	$19,600.00

Ron Mayron Buying and Selling Activity at Entera Bio

Entera Bio Company Overview

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Today's Range

Now: $2.26

$2.19

$2.26

50 Day Range

MA: $1.60

$0.85

$2.98

2 Week Range

Now: $2.26

$0.52

$3.35

Volume

9,629 shs

Average Volume

208,333 shs

Market Capitalization

$65.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7